Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold
- PMID: 9974468
- PMCID: PMC1114914
- DOI: 10.1136/bmj.318.7181.456
Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold
Figures
Comment in
-
Lack of funding will inhibit evidence based commissioning of cancer treatments.BMJ. 2000 Jan 1;320(7226):54. BMJ. 2000. PMID: 10617538 Free PMC article. No abstract available.
References
-
- Calman K, Hine D. A policy framework for commissioning cancer services. London: Department of Health; 1995. p. 18.
-
- Medicines and the NHS: a guide for directors. Drug Therap Bull. 1997;4:1.
-
- Chustecka Z. UK demands taxol for ovarian cancer. Scrip 1998;2338/39:28.
-
- Halle M. Cancer treatments rationed by authority. BMJ. 1996;313:774. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources